Abstract: An object of the present invention is to provide a novel pharmaceutical agent for improving autism spectrum disorder, a pharmaceutical agent for improving a mental disease, or a supplement exerting an effect of improving social behaviors or developing sociality or an anti-anxiety and anti-stress effect or a functional food exerting such an effect. The present invention also provides a pharmaceutical agent for promoting the secretion of oxytocin and/or vasopressin in the brain. The above objects are achieved by a pharmaceutical agent for improving autism spectrum disorder, a pharmaceutical agent for improving a mental disease, or a supplement exerting an effect of improving social behaviors or developing sociality or an anti-anxiety and anti-stress effect or a functional food exerting such an effect, or a pharmaceutical agent for promoting the secretion of oxytocin and/or vasopressin, which comprises D-allulose as an active ingredient.

Abstract: An object of the present invention is to provide a novel pharmaceutical agent for improving autism spectrum disorder, a pharmaceutical agent for improving a mental disease, or a supplement exerting an effect of improving social behaviors or developing sociality or an anti-anxiety and anti-stress effect or a functional food exerting such an effect. The present invention also provides a pharmaceutical agent for promoting the secretion of oxytocin and/or vasopressin in the brain. The above objects are achieved by a pharmaceutical agent for improving autism spectrum disorder, a pharmaceutical agent for improving a mental disease, or a supplement exerting an effect of improving social behaviors or developing sociality or an anti-anxiety and anti-stress effect or a functional food exerting such an effect, or a pharmaceutical agent for promoting the secretion of oxytocin and/or vasopressin, which comprises D-allulose as an active ingredient.

Abstract: An object of the present invention is to provide a GLP-1 secretagogue which is an incretin hormone-related drug relatively inexpensive, excellent in safety, and capable of promoting GLP-1 secretion without containing sucrose as an essential constituent. The object is achieved by a GLP-1 secretagogue characterized by containing D-psicose as an active ingredient.

Abstract: An appetite-suppressing composition is characterized by comprising, as an active component, the liquid component derived from Indian mulberry (Morinda citrifolia). The solution is the liquid component extracted from fermented Indian mulberry fruits, which includes the residual liquid containing the >3,000 component and the filtrated liquid containing the <3,000 component. Considerably, provided is the food that possesses the appetite-suppressing composition without showing the non-specific effect on appetite suppression.

Abstract: Object: To provide an agent for sustaining satiety or a method for sustaining satiety, with which an individual's food intake is reduced by sustaining satiety, and as a result, pathological conditions such as obesity due to overeating can be prevented and improved. Means for Resolution: An agent for sustaining satiety containing D-psicose as an active ingredient and a method for sustaining satiety by the ingestion of D-psicose. Advantageous Effect: Satiety can be sustained although the increase in blood glucose level after eating is suppressed. A means for sustaining satiety which is useful for those who are anxious about their blood glucose level and those who are health conscious can be provided.